• OPEN AN ACCOUNT
Indian Indices
Nifty
26,033.75 47.75
(0.18%)
Sensex
85,747.83 482.51
( 0.57%)
Bank Nifty
59,288.70 -59.55
( -0.10%)
Nifty IT
38,360.25 535.00
( 1.41%)
Global Indices
Nasdaq
47,874.44 -29.46
(-0.06%)
Dow Jones
6,878.17 7.45
(0.11%)
Hang Seng
50,935.81 1,071.13
(2.15%)
Nikkei 225
9,722.32 30.25
(0.31%)
Forex
USD-INR
90.13 0.27
(0.30%)
EUR-INR
105.04 0.70
(0.67%)
GBP-INR
119.76 1.10
(0.93%)
JPY-INR
0.58 0.00
(0.57%)

EQUITY - MARKET SCREENER

Vikas Lifecare Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
542655
INE161L01027
2.9324378
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
VIKASLIFE
0
339.95
EPS(TTM)
Face Value()
Div & Yield %
0
1
0
 

Zydus receives USFDA approval for Leuprolide Acetate injection
Nov 14,2025
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial (USRLD: Lupron Injection®, 1 mg/0.2 mL).

Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer.

Leuprolide Acetate injections will be manufactured at the Company's oncology injectable manufacturing facility at SEZ1, Ahmedabad (‘ALIDAC').

Leuprolide Acetate injection had annual sales of USD 69 mn in the United States (IQVIA MAT Sept 2025).